{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=96&sponsor=M.D.+Anderson+Cancer+Center", "query": { "sponsor": "M.D. Anderson Cancer Center", "page": 96 }, "page_size": 10 }, "pagination": { "page": 96, "page_size": 10, "total_count": 3096, "total_pages": 310, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=97&sponsor=M.D.+Anderson+Cancer+Center&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=95&sponsor=M.D.+Anderson+Cancer+Center&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T23:22:34.511Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06200155", "title": "Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Depression, Anxiety", "Psilocybin-Assisted Psychotherapy", "Advanced Cancer" ], "interventions": [ { "name": "Psilocybin", "type": "DRUG" }, { "name": "Niacin", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": null, "sex": "ALL", "summary": "25 Years and older" }, "enrollment_count": 48, "start_date": "2024-04-16", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-27T23:22:34.511Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06200155" }, { "nct_id": "NCT06967610", "title": "Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Leukemia (SLL)" ], "interventions": [ { "name": "Pirtobrutinib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2025-07-15", "completion_date": "2033-06-01", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-10-27T23:22:34.511Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06967610" }, { "nct_id": "NCT00038649", "title": "Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelogenous Leukemia, Chronic, Chronic Phase" ], "interventions": [ { "name": "Gleevec", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 117, "start_date": "2001-06", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2018-10-09", "last_synced_at": "2026-10-27T23:22:34.511Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00038649" }, { "nct_id": "NCT04902040", "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Bladder Carcinoma", "Advanced Lung Non-Small Cell Carcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Melanoma", "Advanced Merkel Cell Carcinoma", "Advanced Renal Cell Carcinoma", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage III Merkel Cell Carcinoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Clinical Stage IV Merkel Cell Carcinoma AJCC v8", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage III Merkel Cell Carcinoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Merkel Cell Carcinoma AJCC v8", "Stage III Bladder Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage IIIA Bladder Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Bladder Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IVA Bladder Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Bladder Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Avelumab", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Plinabulin", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2021-04-14", "completion_date": "2025-02-27", "has_results": true, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-10-27T23:22:34.511Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04902040" }, { "nct_id": "NCT00496444", "title": "Azacytidine and Valproic Acid in Patients With Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancers" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Valproic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 69, "start_date": "2005-05", "completion_date": "2009-10", "has_results": false, "last_update_posted_date": "2012-08-01", "last_synced_at": "2026-10-27T23:22:34.511Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00496444" }, { "nct_id": "NCT02274493", "title": "Robotic Harvest of the Latissimus Dorsi (LD) Muscles", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Other Reconstructive Surgery", "Failure of Muscle Graft", "Cancer", "Complications", "Surgical Procedure, Unspecified" ], "interventions": [ { "name": "da Vinci® Robotic Surgical System", "type": "DEVICE" }, { "name": "LD muscle flap harvest procedure", "type": "PROCEDURE" }, { "name": "Reconstructive surgery", "type": "PROCEDURE" }, { "name": "Questionnaires", "type": "BEHAVIORAL" } ], "intervention_types": [ "DEVICE", "PROCEDURE", "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2015-07-08", "completion_date": "2018-03-07", "has_results": true, "last_update_posted_date": "2019-03-26", "last_synced_at": "2026-10-27T23:22:34.511Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02274493" }, { "nct_id": "NCT04678414", "title": "Infertility Survey Among Reproductive Age Women With Gynecological and Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage IA Breast Cancer AJCC v8", "Anatomic Stage IB Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Anatomic Stage IIB Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Endometrial Carcinoma", "Female Reproductive System Disorder", "Prognostic Stage I Breast Cancer AJCC v8", "Prognostic Stage IA Breast Cancer AJCC v8", "Prognostic Stage IB Breast Cancer AJCC v8", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Cancer AJCC v8", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Stage I Uterine Corpus Cancer AJCC v8", "Stage IA Cervical Cancer AJCC v8", "Stage IA Ovarian Cancer AJCC v8", "Stage IA Uterine Corpus Cancer AJCC v8", "Stage IA1 Cervical Cancer AJCC v8", "Stage IA2 Cervical Cancer AJCC v8", "Stage IB1 Cervical Cancer AJCC v8", "Stage IC Ovarian Cancer AJCC v8" ], "interventions": [ { "name": "Healthcare Activity", "type": "BEHAVIORAL" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 1410, "start_date": "2019-04-01", "completion_date": "2027-02-02", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-27T23:22:34.511Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04678414" }, { "nct_id": "NCT02600949", "title": "Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Colorectal Adenocarcinoma", "Metastatic Pancreatic Ductal Adenocarcinoma", "Stage IV Colorectal Cancer AJCC v7", "Stage IV Pancreatic Cancer AJCC v6 and v7", "Stage IVA Colorectal Cancer AJCC v7", "Stage IVB Colorectal Cancer AJCC v7" ], "interventions": [ { "name": "Imiquimod", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Sotigalimab", "type": "BIOLOGICAL" }, { "name": "Synthetic Tumor-Associated Peptide Vaccine Therapy", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 119, "start_date": "2016-05-11", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-27T23:22:34.511Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02600949" }, { "nct_id": "NCT00500240", "title": "Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "Insulin Glargine", "type": "DRUG" }, { "name": "Insulin Aspart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 52, "start_date": "2004-04", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2015-06-03", "last_synced_at": "2026-10-27T23:22:34.511Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00500240" }, { "nct_id": "NCT01460498", "title": "Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Azacitidine (AZA)", "type": "DRUG" }, { "name": "Tyrosine kinase inhibitor (TKI)", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 3, "start_date": "2012-08-08", "completion_date": "2019-08-07", "has_results": false, "last_update_posted_date": "2020-03-05", "last_synced_at": "2026-10-27T23:22:34.511Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01460498" } ] }